Asitri Dashboard

Search Clinical Trials

The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.

Saved Searches

Choose Search
Basic Search
Targeted Search

Clinical Trials Search Results

Search History:
Count: 277
Selected: 0
NCT IDTitle
NCT00892697Intrahepatic HCV RNA and Telaprevir Kinetics in Hepatitis C Virus (HCV)
NCT02514473A Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects With CF, Homozygous for the F508del-CFTR Mutation
NCT01807949A Study of Lumacaftor in Combination With Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Who Are Homozygous for the F508del-CFTR Mutation
NCT01886209Phase 1 PK Interaction Study Between VX-509 and Prednisone or Methylprednisolone in Healthy Male Subjects
NCT05818852A Study to Evaluate the Effect of VX-548 on the QT/QTc Interval in Healthy Participants
NCT05560464Evaluation of the Pharmacokinetics and Safety of VX-548 in Participants With Mild or Moderate Hepatic Impairment
NCT00389298A Proof-of-concept Study of VCH-759 for the Treatment of Hepatitis C-infection.
NCT03227094Simplification of CF-related Diabetes Screening at Home
NCT04066751The Multicenter Topic Trial
NCT05668741A Phase 1/2 Study of VX-522 in Participants With Cystic Fibrosis (CF)
NCT06506773Natural History Study of Exocrine Pancreatic Function in Infants With Cystic Fibrosis (CF)
NCT06523595Evaluation of the Pharmacokinetic Drug-drug Interactions Between VX-993 and Metformin in Healthy Adults
NCT02347657A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor
NCT00088504Merimepodib (MMPD) in Triple Combination for the Treatment of Chronic Hepatitis C
NCT03278314Tezacaftor/Ivacaftor Combination Therapy Expanded Access Program for Patients 12 Years of Age and Older With Cystic Fibrosis
NCT01262352Study of the Effect of Ivacaftor on Lung Clearance Index in Subjects With Cystic Fibrosis and the G551D Mutation
NCT01614457Study of Ivacaftor in Subjects With Cystic Fibrosis (CF) Who Have the R117H-CF Transmembrane Conductance Regulator (CFTR) Mutation (KONDUCT)
NCT02722057A Study to Confirm the Long-term Safety and Effectiveness of Kalydeco in Patients With Cystic Fibrosis Who Have an R117H-CFTR Mutation, Including Pediatric Patients
NCT00865904Study of VX-809 in Cystic Fibrosis Subjects With the ∆F508-CFTR Gene Mutation
NCT04167345Evaluation of the Efficacy and Safety of VX-814 in Subjects With the PiZZ Genotype
NCT01821963Telaprevir Plus Standard of Care (SOC) in HCV Associated Hepatocellular Carcinoma (HCC)
NCT00273936Trial of AVN-944 in Patients With Advanced Hematologic Malignancies
NCT03224351A Study Evaluating the Safety and Efficacy of VX-659 Combination Therapy in Subjects With Cystic Fibrosis
NCT03447249A Phase 3 Study of VX-659 Combination Therapy in Subjects With Cystic Fibrosis Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF)
NCT05329649Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Severe Sickle Cell Disease (SCD)
NCT01897233Study of Lumacaftor in Combination With Ivacaftor in Subjects 6 Through 11 Years of Age With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation
NCT00789126Single and Multiple Dose Escalation Study of VX-509 in Healthy Subjects
NCT01275599Drug-Drug Interaction Study Between Telaprevir and Buprenorphine
NCT06886269A Study to Evaluate How the Body Processes 14C-VX-993 After a Single Oral Dose
NCT04208529A Long-term Follow-up Study in Participants Who Received CTX001
NCT05347394A Phase 1 Dose Escalation Study of Oral VX-708 in Healthy Participants
NCT00916474Virology Follow up Study in Subjects Previously Treated With Telaprevir
NCT02141464Energy Balance and Weight Gain With Ivacaftor Treatment
NCT01381289VX-770 Expanded Access Program
NCT04043806A Study Evaluating the Long-term Safety of VX-445 Combination Therapy
NCT03125395A Rollover Safety Study of Lumacaftor/Ivacaftor in Subjects Aged 2 Years and Older With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation
NCT00591214Safety and PK Study of MP-424 to Treat Chronic Hepatitis C
NCT01511432A Study to Assess the Relative Bioavailability Three New Formulations of Telaprevir in Healthy Subjects
NCT03525574A Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy
NCT02871778Clearing Lungs With ENaC Inhibition in Primary Ciliary Dyskinesia
NCT06861413A Phase 1 Study to Evaluate the Relative Bioavailability of a VX-828 Tablet Formulation
NCT06696443Evaluation of the Long-term Safety and Effectiveness of Suzetrigine (SUZ) in Participants With Painful Diabetic Peripheral Neuropathy (DPN)
NCT01830985A Phase 2/3 Open-label Extension Study to Evaluate Long-Term Safety and Efficacy With VX-509 in Subjects With Rheumatoid Arthritis
NCT05437120Pharmacokinetics and Safety Assessment of VX-121/Tezacaftor/Deutivacaftor in Participants With Moderate Hepatic Impairment
NCT03912233A Study to Evaluate the Safety and Efficacy of VX-121 Combination Therapy in Subjects With Cystic Fibrosis
NCT03601637Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Participants 1 to Less Than 2 Years of Age With Cystic Fibrosis, Homozygous for F508del
NCT05865171A Study to Evaluate Pharmacokinetics (PK) and Safety of Inaxaplin in Participants With Renal Impairment
NCT03783286Ivacaftor Treatment in 4 Month to 2 Year Old CF Subjects
NCT01842451A Phase 2 Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of VX-135 and Daclatasvir in Subjects With Genotype 1 Chronic Hepatitis C Chronic Hepatitis C
NCT05704556Evaluation of the Pharmacokinetics and Safety of VX-548 in Participants With Renal Impairment